<DOC>
	<DOCNO>NCT01592981</DOCNO>
	<brief_summary>The purpose trial ass tolerability efficacy Bortezomib , Cyclophosphamide Rituximab combination initial therapy previously untreated patient symptomatic Waldenstrom 's macroglobulinaemia .</brief_summary>
	<brief_title>Randomised Trial Waldenstrom 's Macroglobulinaemia</brief_title>
	<detailed_description>Waldenstrom macroglobulinaemia ( WM ) low grade nonHodgkin lymphoma characterise bone marrow infiltration presence abnormal protein blood ( IgM paraprotein . Most patient require treatment presentation agree standard first line therapy . Current treatment unsatisfactory response often incomplete slow attain , recurrence inevitable . The aim study find whether new combination Bortezomib ( Velcade® ) , Cyclophosphamide Rituximab ( MabThera ) , well tolerated effective patient WM . R2W randomise , noncomparative , phase II trial subcutaneous bortezomib , cyclophosphamide , rituximab ( BCR , experimental arm ) versus fludarabine , cyclophosphamide , rituximab ( FCR , control arm ) initial therapy WM . This two stage trial six patient treat initially BCR assess tolerability . If BCR consider tolerable , 50 patient randomise BCR FCR ( 2:1 ) second stage trial . Patients receive 3 cycle treatment reassess . Those evidence progression stop trial treatment . All patient continue 3 cycle ( total 6 ) unless clear clinical contraindication treatment .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age ≥ 18 year Confirmed diagnosis WM ( accord consensus panel / WHO criteria ) measurable IgM paraprotein Previously untreated disease stage require therapy discretion treat physician . Suggested criterion initiate treatment include : haematological suppression Hb &lt; 10 g/dl , neutrophils &lt; 1.5x109/l platelet &lt; 150x109/l clinical evidence hyperviscosity bulky lymphadenopathy and/or bulky splenomegaly presence B symptoms No previous chemotherapy ( prior plasma exchange steroid permissible ) Performance status grade 0 2 Life expectancy great 6 month Informed consent Agreed compliance recommend contraceptive precaution appropriate Lymphoplasmacytic lymphoma detectable serum IgM paraprotein Severe preexist neuropathy ( &gt; grade 2 ) Autoimmune cytopenias Evidence active Hepatitis B C infection ( patient evidence past HepB infection may eligible see appendix 6 ) Serological positivity HIV Pregnant lactate woman Life expectancy severely limited illness Renal failure ( creatinine clearance &lt; 30 ml/min ) Severe impairment liver function : alkaline phosphatase/bilirubin &gt; 2.5 time upper limit normal ( ULN ) , ALT/AST &gt; 2.5 time ULN related lymphoma ( patient Gilbert syndrome eligible ) History allergic reaction compound contain boron mannitol Known hypersensitivity murine compound . Diagnosed treated malignancy WM within 5 year day 1 Cycle 1 exception complete resection basal cell carcinoma , squamous cell carcinoma skin situ malignancy Active systemic infection require treatment Concurrent treatment another investigational agent Severe lifethreatening cardiac , pulmonary , neurological , psychiatric metabolic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Waldenstrom 's macroglobulinaemia</keyword>
	<keyword>bortezomib</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>rituximab</keyword>
</DOC>